Corgenix Reports New Clinical Data Correlating AtherOx Technology
With Vascular Disease
DENVER--(BUSINESS WIRE)--Jul 10, 2007 - Corgenix MedicalCorporation (OTC BB: CONX) and the Company's clinical collaboratorsreported new clinical data demonstrating a significant correlationbetween serum levels of the Company's patented At
herOx(TM)bio-markers and cardiovascular disease. The data was presented atthe XXIst Congress of the International Society on Thrombosis andHemostasis (ISTH...
Interferon Beta DNA Treatment Delivered with Ichor Technology
Reduces Atherosclerosis Progression in Mice
Summary: Proprietary DNA delivery technology enables sustainedInterferon-beta production from muscle cells - reducesat
herosclerosis progression in mouse model of heart disease NEW ORLEANS--(BUSINESS WIRE)--Mar 26, 2007 - Research conductedat Cleveland Clinic and presented today at the American College ofCardiology's 58th Annual Scientific Session showed that a singleadministration of DNA...
First Study To Show Positive Benefit On Atherosclerosis For People
With Early Signs Of Diseased Arteries
METEOR Trial Shows CRESTOR Slowed Progression Of At
herosclerosisIn People At Low-Risk* Of Coronary Heart Disease LONDON, March 26, 2006-AstraZeneca today announced that theMETEOR clinical trial of CRESTOR is the first study to show apositive effect on at
herosclerosis in people with early signs ofcarotid artery disease and at low risk of coronary heart disease(CHD). The study...
Two New Imaging Studies Show Higher Dose Lipitor Stopped the
Progression of Atherosclerosis
NEW ORLEANS--(BUSINESS WIRE)--Mar 26, 2007 - Pfizer said today thatresults from two new imaging trials showed that higher dose Lipitorstopped the progression of at
herosclerosis in patients withcoronary heart disease or familial hypercholesterolemia (FH). Thetrials, which were designed to investigate the efficacy of theformer investigational compound torcetrapib in combination withLipitor co...
REACH Registry Demonstrates That Multiple Arterial Disease
Locations Sharply Increase the Risk of Major CV Events in
Outpatients With Atherothrombosis
- The Reduction of At
herothrombosis for Continued Health(REACH) PARIS, March 20, 2007 /PRNewswire/ --The REACH Registry 1-yearresults paper published today in the Journal of the AmericanMedical Association (JAMA) show that outpatients withat
herothrombosis have a surprisingly high risk of death or majorcardiovascular illness, especially if more than...
AtheroGenics Reports ARISE Trial Results for AGI-1067
Full Study Resultsto Be Presented at the American College of Cardiology's ScientificSession WIRE) -- 03/19/2007 -- At
heroGenics, Inc. (NASDAQ: AGIX) todayannounced that its ARISE Phase III clinical study of its lead drugcandidate, AGI-1067, did not show a difference from placebo in itscomposite primary...